Clinical-stage biotechnology company IgGenix Inc announced on Wednesday that the first patient has been dosed in its ACCELERATE Peanut Phase 1 clinical trial of IGNX001, a novel therapeutic candidate developed using IgGenix's proprietary SEQ SIFTER platform.

The trial is intended to assess IGNX001 in patients with peanut allergy. Engineered to neutralise the most clinically important peanut allergens and epitopes, IGNX001 represents a novel approach to combat peanut allergies by blocking the allergic cascade.

ACCELERATE Peanut Phase 1 is a randomised, multi-centre, double-blind, placebo-controlled, single ascending dose study evaluating the safety, tolerability and potential proof of mechanism of IGNX001 in peanut-allergic individuals. The trial will enrol around 24 adults and older adolescents (aged 15 to 18) who have been diagnosed with peanut allergy.

Jessica Grossman MD, IgGenix CEO, said: "IGNX001 embodies years of rigorous research and development, and this milestone marks an important step toward validating our mechanism of action in allergy treatment. Preclinical data have demonstrated the potential of IGNX001 to have greater impact for patients living with peanut allergy, particularly through its expected rapid onset of action, improved safety profile, and less frequent subcutaneous injection schedule. We look forward to reporting topline data in mid-2025 and progressing IGNX001 through the clinic."